Followers | 218 |
Posts | 38765 |
Boards Moderated | 0 |
Alias Born | 04/29/2008 |
Saturday, October 01, 2016 5:06:09 AM
KalVista investors have doubled their money.
CBYL investors are getting a 60% reduction in the value OF THEIR CASH, not to mention a 90% reduction in the value of their total invested cash.
All this for a company that has 1 drug that finished phase I testing and another (for a disease that affects 1:10,000 people) that is just starting phase I testing.
As of 6/30, CBYL has $1.37 in positive book value, KalVista has negative $18.69.
How the CBYL board and large shareholders can continue to support a transaction which clearly the market feels is bad for the company is beyond me.
I urge all shareholders to vote against the transaction and force the company to liquidate and at least get us back to $1/share value.
TA - Over $500 million in toxic funded pump and dumps exposed and growing every day!
Recent KALV News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/02/2024 10:30:00 AM
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year • Business Wire • 05/01/2024 10:30:00 AM
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors • Business Wire • 04/22/2024 10:30:00 AM
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/03/2024 10:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2024 10:30:00 AM
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas • Business Wire • 03/18/2024 10:30:00 AM
- KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat • Business Wire • 03/12/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:37:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/11/2024 08:26:19 PM
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update • Business Wire • 03/11/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:50:45 PM
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas • Business Wire • 03/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:38:33 AM
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer • Business Wire • 03/07/2024 11:30:00 AM
- KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/06/2024 11:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/04/2024 11:30:00 AM
- KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • Business Wire • 02/27/2024 11:30:00 AM
- KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • Business Wire • 02/26/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:15:27 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/22/2024 06:22:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:51:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:48:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:46:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:44:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:41:48 AM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM